NanoString Launches New Genomics and Proteomics Research Products for Advanced Precision Oncology at AACR 2017

Booth #3115

4 Apr 2017
Lois Manton-O'Byrne
Executive Editor

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, is releasing multiple new products at the American Association of Cancer Research (AACR) Meeting 2017. The new products build on NanoString's existing portfolio of products that leverage genomics and proteomics to advance precision oncology.

"We continue to enhance the capabilities and expand the content for our nCounter platform. Our goal is to deliver best-in-class solutions that address the complex challenges that are inherent in precision oncology," said Brad Gray, president and chief executive officer of NanoString Technologies.

New products released include the following:

  • The nCounter Low RNA Input Kit enables nCounter Gene Expression analysis to be performed with sample inputs ranging from 1-10 ng, depending on sample quality. The kit is compatible with NanoString's panel products as well as custom offerings. It utilizes Multiplexed Target Enrichment (MTE) to linearly amplify mRNA sample transcripts and is compatible with a wide range of sample types including Formalin Fixed Parafin Embedded (FFPE) tissue.
  • The nCounter® Vantage 3D™ RNA MAPK-PI3K Pathways Panel provides a curated gene set measuring transcriptional activity of the MAPK and PI3K pathways on the nCounter® platform. Seminal publications focused on MAPK and PI3K research and signature development were collated and scored to develop this panel, which captures the diverse set of biological functions that the MAPK and PI3K pathways modulate. As part of the Vantage 3D™ portfolio, these panels pair with the Vantage 3D DNA SNV and Protein Solid Tumor Panels for integrated DNA, RNA, and protein quantification in solid tumor research.
  • The Intracellular Compatible Universal Cell Capture Kit enables the nCounter Vantage 3D RNA:Protein Immune Cell Signaling Assay with as few as 20,000 cells for expression analysis of 770 RNA and 26 key intracellular proteins, including cytokines, chemoattractants, and transcription factors. In combination with the new Low RNA Input Kit, both the Vantage 3D RNA:Protein Immune Cell Profiling and Immune Cell Signaling Assay provide in depth immune characterization from minimal sample.
  • The nCounter Myeloid Innate Immunity Panels provide researchers studying the role of myeloid innate immune response in cancer and other diseases a tool for rapid, comprehensive gene expression profiling of human or mouse RNA. Designed in partnership with Lisa Coussens, Ph.D., of Oregon Health and Sciences University, the panels enable quantitative evaluation of heterogeneous myeloid cell populations based on the differentiation and maturation status as well as functional activities.

NanoString is also featured in more than 50 presentations and posters that will be presented throughout the conference.

Links

Tags